Phase I Study of the Combination of MLN9708 and Fulvestrant in Patients With Advanced Estrogen Receptor Positive Breast Cancer

Trial Profile

Phase I Study of the Combination of MLN9708 and Fulvestrant in Patients With Advanced Estrogen Receptor Positive Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Ixazomib (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms Millennium
  • Most Recent Events

    • 08 Mar 2018 Planned End Date changed from 1 May 2019 to 1 Aug 2019.
    • 08 Mar 2018 Planned primary completion date changed from 1 May 2018 to 1 Aug 2018.
    • 25 Mar 2017 Planned End Date changed from 1 May 2018 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top